Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Single-Dose, Open Label, Pharmacokinetic and Pharmacodynamic Study of RDEA3170 in Adult Male Subjects With Mild, Moderate, and Severe Renal Impairment

NCT02219516 is registered in ClinicalTrials.gov with Ardea Biosciences, Inc. as lead sponsor.

NCT NCT02219516
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02219516 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Single-Dose, Open Label, Pharmacokinetic and Pharmacodynamic Study of RDEA3170 in Adult Male Subjects With Mild, Moderate, and Severe Renal Impairment
Lead sponsor
Ardea Biosciences, Inc.
Phase
Phase 1
Overall status
Completed
Start date
August 1, 2014
Completion date
May 13, 2016
Enrollment
31 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

gout